Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the biotechnology company’s stock.

Several other equities research analysts also recently weighed in on the company. Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Price Performance

ATXS stock traded down $0.74 during midday trading on Thursday, reaching $9.35. 132,323 shares of the company’s stock traded hands, compared to its average volume of 613,292. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The business has a 50-day moving average price of $11.44 and a two-hundred day moving average price of $10.60. The company has a market capitalization of $527.53 million, a P/E ratio of -4.44 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, research analysts forecast that Astria Therapeutics will post -1.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after acquiring an additional 480,184 shares in the last quarter. Tidal Investments LLC acquired a new stake in shares of Astria Therapeutics in the 1st quarter valued at about $1,664,000. Sofinnova Investments Inc. bought a new position in shares of Astria Therapeutics during the second quarter worth about $552,000. ClariVest Asset Management LLC acquired a new position in Astria Therapeutics in the second quarter worth about $731,000. Finally, Ameritas Investment Partners Inc. increased its holdings in Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 2,861 shares during the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.